Dr. Seung-Jung Park
Crazy Left Main Stenting
Dr. Seung-Jung Park (South Korea) is a Chair Professor at the University of Ulsan, Asan Medical Center in Seoul, Korea. He advanced left main (LM) stenting as an alternative to CABG, demonstrated that IVUS-guided stenting leads to better outcomes, and emphasized the utilization of Fractional Flow Reserve (FFR) for optimizing patient care. He conducted a groundbreaking study on preventive PCI for non-ischemic vulnerable plaques, known as the PREVENT study. With over 724 papers, he has led landmark trials such as MAINCOMPARE, DES-LATE, PRECOMBAT, BEST, DECISION CTO, OCTIVUS, POST-PCI and PREVENT, which were primarily published in NEJM and The Lancet. He is the founder of the CardioVascular Research Foundation (CVRF) and TCTAP. His contributions have earned numerous prestigious awards, including the Andreas Grüntzig Ethica Award at EuroPCR (2005), the Career Achievement Award at TCT (2008), the Asan Medical Award (2011) and the Ho-Am Prize in Medicine (2020).
Dr. Park was a pioneer and is the leader in the treatment of Left Main Intervention. (Gary S. Mintz) It is a major achievement. Let's say having one article once for a person. But something major four times? Only very few people do that, so Dr. Park is a major contributor. (Marie-Claude Morice) First, Dr. Park, as a leader with regard to technique, certainly has been a pioneer in helping us to innovate new ways to manage complex coronary disease. (Martin Bert Leon) Dr. Park has actually now become one of the world’s foremost proponents on how to use fractional flow reverse. There’s no room for error in treating the left main, and more than 30 years ago, it was demonstrated that coronary artery bypass graft surgery, compared to medical therapy, is the standard of care. But this was met with a lot of skepticism by the general medical community and surgeons in particular. It is extremely difficult to get an article published in the New England Journal. It might be, you know, at most 5 out of 100 papers that get submitted to the New England Journal, whatever gets published. And these are only the best of the best. (Gregg W. Stone)
Dr. Seung-Jung Park (South Korea) is a Chair Professor at the University of Ulsan, Asan Medical Center in Seoul, Korea. He advanced left main (LM) stenting as an alternative to CABG, demonstrated that IVUS-guided stenting leads to better outcomes, and emphasized the utilization of Fractional Flow Reserve (FFR) for optimizing patient care. He conducted a groundbreaking study on preventive PCI for non-ischemic vulnerable plaques, known as the PREVENT study. With over 724 papers, he has led landmark trials such as MAINCOMPARE, DES-LATE, PRECOMBAT, BEST, DECISION CTO, OCTIVUS, POST-PCI and PREVENT, which were primarily published in NEJM and The Lancet. He is the founder of the CardioVascular Research Foundation (CVRF) and TCTAP. His contributions have earned numerous prestigious awards, including the Andreas Grüntzig Ethica Award at EuroPCR (2005), the Career Achievement Award at TCT (2008), the Asan Medical Award (2011) and the Ho-Am Prize in Medicine (2020).
Dr. Park was a pioneer and is the leader in the treatment of Left Main Intervention. (Gary S. Mintz) It is a major achievement. Let's say having one article once for a person. But something major four times? Only very few people do that, so Dr. Park is a major contributor. (Marie-Claude Morice) First, Dr. Park, as a leader with regard to technique, certainly has been a pioneer in helping us to innovate new ways to manage complex coronary disease. (Martin Bert Leon) Dr. Park has actually now become one of the world’s foremost proponents on how to use fractional flow reverse. There’s no room for error in treating the left main, and more than 30 years ago, it was demonstrated that coronary artery bypass graft surgery, compared to medical therapy, is the standard of care. But this was met with a lot of skepticism by the general medical community and surgeons in particular. It is extremely difficult to get an article published in the New England Journal. It might be, you know, at most 5 out of 100 papers that get submitted to the New England Journal, whatever gets published. And these are only the best of the best. (Gregg W. Stone)